Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +46.08%
#3 Glidr Glidr +35.94%
#4 Cysic Cysic +32.50%
#5 Walrus Walrus +23.65%
#6 Tutorial Tutorial +23.18%
#7 Enso Enso +18.12%
#8 Humanity Humanity +18.02%
#9 Codatta Codatta +14.33%
#10 Huma Finance Huma Finance +13.74%
Coin of the day
EXOD EXOD
Instellingen
Taal
DUTCH
Valuta
USD
Thema
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Limited

ASLN
Rang in aandelen #37031
ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the... ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the clinical stage, primarily focused on immunology, and dedicated to creating innovative treatments that profoundly enhance patients' lives. Its advanced therapeutic pipeline features ASLAN004, a monoclonal antibody currently being evaluated for atopic dermatitis and a range of other immunological disorders. Also under development is ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase, intended to treat autoimmune conditions. The company is involved in a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd., aimed at pioneering immuno-oncology therapeutics that target the AhR pathway. Furthermore, ASLAN maintains partnerships with various entities, including Almirall, Array BioPharma, and CSL Limited. Established in 2010, the company's headquarters are located in Singapore.
Aandeelprijs
$0.6
Laatst gesynchroniseerd: 2024-08-14
Marktkapitalisatie
$2.09M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
SG
Handel ASLAN Pharmaceuticals Limited (ASLN)

Categorie

Healthcare
P/S-ratio voor ASLAN Pharmaceuticals Limited (ASLN)
P/S-ratio op August 2026 TTM: 64.76
Volgens de meest recente financiële rapporten en aandelenkoers van ASLAN Pharmaceuticals Limited is de huidige P/S-ratio (TTM) 64.76. Eind 2022 had het bedrijf een P/S-ratio van 0.00.
P/S-ratiohistoriek voor ASLAN Pharmaceuticals Limited van 2014 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
2026 (TTM) 64.76 28,056.61%
2023 0.23 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 -100.00%
2019 7.03 0.00%
2018 0.00 0.00%
2017 0.00 -100.00%
2016 4.07 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
P/S-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/S-ratio Verschil in P/S-ratio Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -84.30%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -84.36%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.74 -92.68%
BE